Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted...
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth
Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth...
Barchart Research What to Expect from GH Earnings GH Generated July 29, 2026 Current Price $144.16 EPS Estimate $$-0.74 Consensus Rating Strong Buy Average Move 10.12% Guardant Health Earnings: Analysts...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord...
Guardant Health (GH) Q2 Earnings Report Preview: What To Look For
Dempsey is calling on Americans to prioritize getting screened and highlighting the innovative Shield blood test for CRC screening Guardant's Shield blood...